bluebird bio (NASDAQ:BLUE) has received a short term rating of sell from experts at Zacks with a rank of 4. The stock has been rated an average of 1.5 by 12 Brokerage Firm. 9 Wall Street Firms have rated the stock as a strong buys. 3 Brokerage Firms have advised hold.
Other Equity analysts have also commented on the company shares. Cantor Fitzgerald initiates coverage on bluebird bio (NASDAQ:BLUE) In a research note issued to the investors, the brokerage major announces price-target of $42 per share.The shares have been rated Hold. The rating by the firm was issued on June 2, 2016.
bluebird bio (NASDAQ:BLUE): The stock price is expected to reach $ 89.55 in the short term. The number of analysts agreeing with this consensus is 11. The higher estimate for the short term price target is at $164 while the lower estimate is at $42. The standard deviation of the price stands at $37.1.
bluebird bio (NASDAQ:BLUE) witnessed a decline in the market cap on Tuesday as its shares dropped 3.38% or 1.39 points. After the session commenced at $41.48, the stock reached the higher end at $41.785 while it hit a low of $39.3301. With the volume soaring to 988,068 shares, the last trade was called at $39.79. The company has a 52-week high of $181.4899. The company has a market cap of $1,470 million and there are 36,943,048 shares in outstanding. The 52-week low of the share price is $35.37.
bluebird bio, Inc. has lost 0.72% in the last five trading days and dropped 2% in the last 4 weeks. bluebird bio, Inc. has dropped 13.71% during the last 3-month period . Year-to-Date the stock performance stands at -38.04%.
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Companys products include Lenti-D, LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy), the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States, Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.